A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.

Trial Details

NCT ID
NCT07684612
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Mocertatug rezetecan (Mo-Rez)
  • Carboplatin
  • Paclitaxel
  • Gemcitabine
  • Pegylated liposomal doxorubicin (PLD)
  • Bevacizumab
Locations (sample)
  • Newcastle, New South Wales, Australia|-32.92953,151.7801
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Hokkaido, Japan
  • Hyōgo, Japan|43.36667,144.43333

Key Eligibility Criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed…
  • Has epithelial ovarian, primary peritoneal, or fallopian-tube cancer with a histologically confirmed diagnosis of high grade serous, high grade end…
  • Has recurrent or progressive disease after completion of at least 1 and a maximum of 2 previous lines of systemic anticancer therapy. Recurrent or …
  • Adjuvant ± neoadjuvant is considered one line of therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →